Archive
KCOM rings up strong gains as the telecoms group agrees to £504mln cash takeover bid
Some of the main news-driven risers and fallers in London on Wednesday...
Company
Shield Therapeutics PLC
LON:STX
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer ® /Feraccru ® (ferric maltol). The group has launched Accrufer® in the US and Feraccru ® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical for the development and commercialization of Accrufer ® / Feraccru ® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co in the Republic of Korea, and with KYE Pharmaceuticals in Canada.
175 stories · page 7 of 9
Shield Therapeutics wins extended approval for Feraccru in Switzerland
The company is encouraged by progress being made with regulatory authorities ahead of an expected decision from US regulators in late July
Archive
FTSE 100 closes in the red as resource stocks come off the boil
After hitting a six-month high on Tuesday afternoon, London's blue-chips took a step back on Wednesday
Archive
Stagecoach and Winkworth trade strongly, Lighthouse lit up on Quilter deal
Here's a look at Wednesday's big share price movers.
Archive
Proactive news snapshot: Chariot Oil & Gas, African Battery Metals, AdEPT Technology, Minds + Machines …
A glance at some of the day's highlights from the Proactive Investors newswire
Shield Therapeutics targeting more lucrative Feraccru out-licence deals in 2019
One deal covering Europe, Australia and New Zealand helped to significantly bump up Shield’s 2018 results and the plan is to sign more lucrative agreements covering China and the US
Archive
FTSE 100 finishes higher as Brexit rumblings continue
Footsie gained around 27 points at 7,418, while FTSE 250 added 234 points at 19,563
Archive
AA’s performance to be eyed on Wednesday for any signs of possible breakdown
Investors will be looking to see if the breakdown services firm can continue its recent run of good fortune
Archive
Proactive news snapshot: Iofina, Circassia Pharma, Directa Plus, Instem …
A glance at some of the day's highlights from the Proactive Investors newswire
Shield Therapeutics says European Patent Office decides in company’s favour in relation to a Feracru patent
The AIM-listed firm said that the decision, made by the EPO’s opposition division, related to patent #2 668 175, which covers a "Process for preparing an iron hydroxypyrone"
Archive
Proactive news snapshot: NetScientific, Capital Drilling, Horizonte Minerals …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
GAN trumpets winning of an industry award ... the shares fall
A look at the day's major movers, including Gulf Marine Services, Boxhill, Chesterfield Resources, Proton Power, Abcam, Tandem, Red Emperor and FFI
Archive
Proactive news snapshot: Shield Therapeutics, Plexus Holdings, 88 Energy …
A glance at some of the day's highlights from the Proactive Investors newswire
Shield Therapeutics’ Feraccru iron deficiency drug shows its mettle in head-to-head study
In the year-long phase IIIb study, Feraccru was shown to deliver “comparable” results to Ferinject, the current standard of care injection given to patients with iron deficiency
Archive
Proactive news snapshot: Shield Therapeutics, ANGLE, Westminster Group …
A glance at some of the day's highlights from the Proactive Investors newswire
Shield Therapeutics' shares rise as it hails results of extended trial of Feraccru
The extended 52-week open-label trial showed increased haemoglobin levels
Archive
Proactive news snapshot: Primary Health Properties, Circassia Pharmaceuticals, Shield Therapeutics …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
AorTech in good heart
A look at the day's major movers, including Tri-Star Resources, Quixant, Metals Exploration, NCC Group, Primary Health Properties, MedicX Fund, Nautical Marine Services, Blue Star Capital and Gama Aviation.
Shield Therapeutics funded through to 2020
Shield expects the results from its head-to-head study on Feraccru this quarter and a decision by the FDA on US approval by the end of July